LXEO — Lexeo Therapeutics Inc · catalysts, narrative & risks

Lexeo Therapeutics (NASDAQ: LXEO) — Research Summary

As of 2026-10-30, Lexeo is a clinical-stage genetic-medicine company using adeno-associated virus (AAV) delivery to target cardiovascular and CNS genetic diseases with high unmet need. Its two lead programs are LX2006 for Friedreich's ataxia (FA) cardiomyopathy and LX2020 for PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM), alongside a candidate for APOE4-related Alzheimer's disease (LX1001) [2][3][12][15]. Market capitalization is roughly $251 million, with a share price near $3.06 as of 2026-10-29 [12][15].

Key Recent Catalysts (last ~1–3 months)